RT Journal Article
SR Electronic
T1 The female protective effect against autism spectrum disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.29.21253866
DO 10.1101/2021.03.29.21253866
A1 Emilie M. Wigdor
A1 Daniel J. Weiner
A1 Jakob Grove
A1 Jack M. Fu
A1 Wesley K. Thompson
A1 Caitlin E. Carey
A1 Nikolas Baya
A1 Celia van der Merwe
A1 Raymond K. Walters
A1 F. Kyle Satterstrom
A1 Duncan S. Palmer
A1 Anders Rosengren
A1 Jonas Bybjerg-Grauholm
A1 iPSYCH Consortium
A1 David M. Hougaard
A1 Preben Bo Mortensen
A1 Mark J. Daly
A1 Michael E. Talkowski
A1 Stephan J. Sanders
A1 Somer L. Bishop
A1 Anders D. Børglum
A1 Elise B. Robinson
YR 2021
UL http://medrxiv.org/content/early/2021/04/05/2021.03.29.21253866.abstract
AB Autism spectrum disorder (ASD) is diagnosed 3-4 times more frequently in males than in females. Genetic studies of rare variants support a female protective effect (FPE) against ASD. However, sex differences in common, inherited genetic risk for ASD are less studied. Leveraging the nationally representative Danish iPSYCH resource, we found siblings of female ASD cases had higher rates of ASD than siblings of male ASD cases (P < 0.01). In the Simons Simplex and SPARK collections, mothers of ASD cases carried more polygenic risk for ASD than fathers of ASD cases (P = 7.0 × 10−7). Male unaffected siblings under-inherited polygenic risk (P = 0.03); female unaffected siblings did not. Further, female ASD cases without a high-impact de novo variant over-inherited nearly three-fold the polygenic risk of male cases with a high-impact de novo (P = 0.02). Our findings support a FPE against ASD that includes common, inherited genetic variation.Competing Interest StatementDSP is an employee of Genomics plc. All the analyses reported in this paper were performed as part of DSP's previous employment at the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. All other authors declare no competing interests.Funding StatementThis work was supported by the Autism Science Foundation (ASP 001 to SJS, ASP 002 to SLB, ASP 003 to EBR) and the NIMH (RMH111813A to EBR; U01MH111662 to SJS). DJW was supported by NLM grant T15LM007092. The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), the EU H2020 Program (Grant No. 667302, 'CoCA' to ADB), NIMH (1U01MH109514-01 to ADB) and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB). This research has been conducted using data from UK Biobank, a major biomedical database, under Project 31063. The authors would like to deeply thank all participants in the cohorts included in this analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are: This study was reviewed and approved by Partners Human Research of Partners HealthCare. The study name is Molecular Study of Cognitive and Behavioral Variation (IRB: 2015P002376). The Principle Investigator is Elise Robinson.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesiPSYCH: Data availability is limited due to the sensitive nature of the data. The iPSYCH Consortium is working with GDPR compliant models for remote access; please contact authors Preben Bo Mortensen and Anders D. Børglum for more details.The imputed SPARK dataset used in this analysis has been given to the Simons Foundation Autism Research Initiative (SFARI) for public distribution. Scientists wishing to access the data set can do so through application to SFARI.HapMap 3 data are available here: https://www.sanger.ac.uk/resources/downloads/human/hapmap3.htmlUK Biobank: approved researchers can access the data by applying at https://www.ukbiobank.ac.uk/enable-your-research/apply-for-accessHaplotype Reference Consortium. Researchers can impute genotypes using the HRC reference data at the following sites: https://imputation.sanger.ac.uk/, https://imputationserver.sph.umich.edu/https://base.sfari.orghttps://www.sanger.ac.uk/resources/downloads/human/hapmap3.htmlhttps://www.ukbiobank.ac.uk/enable-your-research/apply-for-accesshttps://imputation.sanger.ac.uk/https://imputationserver.sph.umich.edu/https://sites.google.com/a/broadinstitute.org/ricopili/preimputation-qc